Conroy P J, Von Burg R, Penney D P, Passalacqua W, Sutherland R M
Br J Cancer. 1980 Apr;41(4):523-8. doi: 10.1038/bjc.1980.94.
I.p. administration at several dose levels over periods of up to 12 weeks, or continuous i.v. infusion of high doses of misonidazole (MISO) for 15 h, produced no significant change in peripheral nerve conduction velocity (NCV) and did not prevent the normal increase in NCV as the animals matured from 12 to 24 weeks of age. Peripheral NCV (sural nerve) was reduced in both MISO-treated and control mice with hind-limb tumour implants, presumably owing to physical pressure due to tumour growth. In addition, neither the medial nerves nor the tibial nerve in the normal limbs of the tumour-implanted, drug-treated animals showed any change. Consequently our earlier and present studies do not confirm the recent reports of changes in NCV following either acute or chronic MISO administration to mice.
腹腔注射不同剂量米索硝唑（MISO）长达12周，或连续静脉输注高剂量米索硝唑15小时，均未导致外周神经传导速度（NCV）出现显著变化，也未阻止动物从12周龄成熟至24周龄期间正常的神经传导速度增加。在后肢植入肿瘤的米索硝唑治疗组和对照组小鼠中，外周神经传导速度（腓肠神经）均降低，这可能是由于肿瘤生长造成的物理压迫所致。此外，植入肿瘤并接受药物治疗的动物正常肢体中的内侧神经和胫神经均未显示出任何变化。因此，我们之前和目前的研究均未证实近期关于对小鼠急性或慢性给予米索硝唑后神经传导速度发生变化的报道。
